Where does AOP Orphan Pharmaceuticals AG rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), AOP Orphan Pharmaceuticals AG ranks #34,261 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does AOP Orphan Pharmaceuticals AG hold?

AOP Orphan Pharmaceuticals AG holds 7 US utility patents granted between 2017 and 2024, spanning 4 technology areas.

What is AOP Orphan Pharmaceuticals AG's Innovation Score?

AOP Orphan Pharmaceuticals AG has an Innovation Score of 25.3 out of 100 (17th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does AOP Orphan Pharmaceuticals AG focus on?

AOP Orphan Pharmaceuticals AG's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 6 patents, ranking #2,984 of 6,058 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is AOP Orphan Pharmaceuticals AG's patent grant rate increasing or decreasing?

AOP Orphan Pharmaceuticals AG's recent grant velocity is +150% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for AOP Orphan Pharmaceuticals AG's patents?

AOP Orphan Pharmaceuticals AG's patents average 12.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the AOP Orphan Pharmaceuticals AG patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

AOP Orphan Pharmaceuticals AG

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, AOP ranks #34,261 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#34,261
of 49,997 US assignees by volume: 17th percentile
by Innovation Score (25.3/100): 12.9
avg claims per patent: +150%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R34261 · Foreign Corporation #34,261 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #34,261/49,997
PHOTO-FINISH ANSeeN
CPC-NARROW A61P · 4 areas
INNOV-THIN 25.3/100
CLAIMS-RICH 12.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +150% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: ANSeeN Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How AOP’s 25.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (28%) Velocity 3.3 pts (13%) Breadth 7.1 pts (28%) Claim depth 7.7 pts (30%)

Qualcomm Incorporated · highest

85
AOP Orphan Pharmaceu… · this assignee

25
Fuji Kiko · near

25
Gammill · near

25
Compagnie Mediterran… · near

25
Mondi Consumer… · near

25
3D Lighting… · lowest

7

What this shows AOP's Innovation Score is 25.3/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for AOP?

Each dot is one of AOP’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). AOP’s own 12.9 claims/patent is at or below the 13.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

AOP vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where AOP's grants concentrate

AOP Orphan Pharmaceuticals AG is a focused PatentsView assignee: 4 CPC subclasses with 85.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2017. By volume, AOP sits between ANSeeN Inc. and APL Technology AS.

AOP's three-year grant acceleration

AOP Orphan Pharmaceuticals AG shows 2 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Anseen

7
ANT Applied New

7
Anteo PTY

7
Aobiome

7
APB

7
Aperture Medical…

7
Apirx Pharmaceuti…

7
APL Technology AS

7
AOP Orphan Pharma… ◀

7

What this shows AOP holds 7 patents at rank #34,158, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near AOP

By rank, the assignees closest to #34,158 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in AOP's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for AOP, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), AOP ranks #2,984 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (25 here).

Gammill, Inc. 25 Fuji Kiko Co., Ltd. 25 Compagnie Mediterraneenne DES Cafes 25 Mondi Consumer Packaging Technologies GMBH 25

AOP's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 17th percentile higher than 17% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

AOP Orphan Pharmaceuticals AG patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	14.3%
2019	1	14.3%
2020	2	28.6%
2021	1	14.3%
2022	1	14.3%
2024	1	14.3%

Which technologies does AOP Orphan Pharmaceuticals AG patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 2

C07D - Heterocyclic Compounds 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

AOP Orphan Pharmaceuticals AG's patent record in context - here's where to go next.

AOP Orphan Pharmaceuticals AG's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #34,261 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare AOP Orphan Pharmaceuticals AG against ANSeeN Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.